ArticleNature communications2017
Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 256 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
256 citing papers in PubMed, 426 citations in OpenAlex.
- The differential impact of three different NADNature metabolism · 2026Trial
- Identification of a candidate PRODH allosteric inhibitor MBTP-15324: modulation of proline metabolite profiles and ECM-associated gene-expression changes in lung cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Proline-Derived N-Heterocyclic Carbene Gold(I) Complexes With Dual DNA Binding and Thioredoxin Reductase Inhibition.ChemMedChem · 2026Article
- Palmitate promotes liver metastases by decreasing neutrophil antitumour behaviour.Nature metabolism · 2026Article
- Targeting the Lipid Metabolism Proteins FASN and GPAM in Alveolar Type II Cells Decreases Lung Metastasis.Cancer discovery · 2026Article
- Deciphering glutamine metabolic reprogramming: a novel therapeutic target ALDH18A1 in triple-negative breast cancer.Scientific reports · 2026Article
- CoQExperimental & molecular medicine · 2026Review
- Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells.Chinese medicine · 2026Article
- Structural Principles of Covalent Flavin Modification in Oxidoreductases.Biochemistry · 2026Review
- Palmitoylation-mediated regulation of KAT2A promotes lung metastasis in breast cancer.Nature cell biology · 2026Article
- Dihydroartemisinin Unravels Dose-Dependent Transcriptomic Networks Orchestrating Ferroptosis and Metabolic Reprogramming in Colorectal Cancer.Current issues in molecular biology · 2026Article
- Arginine dependency in omental metastasis of epithelial ovarian cancer reveals a therapeutic vulnerability.Cell death & disease · 2026Article
- Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Exploring metabolic dynamics of cancer metastasis through in vitro models.Discover oncology · 2026Review
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- Quantifying Mitochondrial Metabolism and Metabolic Fluxes in Soft Agar Cultures.Methods in molecular biology (Clifton, N.J.) · 2026Article
- The key enzyme PYCR1 in proline metabolism: a dual driver of cancer progression and fibrotic remodeling.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Serum metabolomics reveals distinctive signature of cancer staging in oral squamous cell carcinoma.BMC oral health · 2025Article
- PRODH2-Mediated Metabolism in the Bone Microenvironment Promotes Breast Cancer Metastasis.Cancer research · 2025Article
196 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastases are the leading cause of mortality in patients with cancer. Metastasis formation requires cancer cells to adapt their cellular phenotype. However, how metabolism supports this adaptation of cancer cells is poorly defined. We use 2D versus 3D cultivation to induce a shift in the cellular phenotype of breast cancer cells. We discover that proline catabolism via proline dehydrogenase (Prodh) supports growth of breast cancer cells in 3D culture. Subsequently, we link proline catabolism to in vivo metastasis formation. In particular, we find that PRODH expression and proline catabolism is increased in metastases compared to primary breast cancers of patients and mice. Moreover, inhibiting Prodh is sufficient to impair formation of lung metastases in the orthotopic 4T1 and EMT6.5 mouse models, without adverse effects on healthy tissue and organ function. In conclusion, we discover that Prodh is a potential drug target for inhibiting metastasis formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.